“`html
Phibro Animal Health Corporation (PAHC) has seen its shares rise by 82.1% in 2023, significantly surpassing the industry average growth of 5.3% and the S&P 500’s 14.2%. The New Jersey-based company reported a 77% year-over-year increase in sales for Medicated Feed Additives and other products in the fourth quarter of fiscal 2025, aided by the acquisition of Zoetis’ MFA portfolio.
Phibro operates approximately 800 product lines across 90 countries, focusing on food and companion animals. Key markets include Brazil, China, and India. The company is currently expanding its vaccine manufacturing capabilities, with a new facility in Guarulhos, Brazil, contributing to a 21% rise in vaccine sales year-over-year.
Despite strong performance, Phibro faces challenges due to economic sanctions and conflicts stemming from the Russia-Ukraine war, which could impact profitability. The Zacks Consensus Estimate forecasts earnings per share of $2.57 for fiscal 2026, an increase of 22.9% year-over-year, with projected revenues of $1.47 billion.
“`
